Author

E. Gobbini

h-index 18 View on Semantic Scholar

We have 3 of 90 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non–Small Cell Lung Cancer

Abstract Non–small cell lung cancer (NSCLC) is responsible for the majority of cancer-related mortality worldwide. Lung adenocarcinoma is the most common NSCLC subtype. Despite advances in targeted therapies, treatment resistance remains a critical challenge. Ribonucleotide reductase (RNR), a crucial enzyme in deoxyrib...

Utsav Sen, Dalia Natour, Subhamoy Chakraborty et al. · Cancer Research Communicatio... · 0 citations

Review Sep 2026

Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer.

This review addresses the limitations of currently used biomarkers across lung cancer histologies and describes emerging immune-related biomarkers encompassing innate immune infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling that have shown promise as histology-independ...

E. Gobbini, Subhamoy Chakraborty, I. Vathiotis et al. · Cancer immunology research · 0 citations

Open access Aug 2026

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

Background Extensive-disease small-cell lung cancer (ED-SCLC) is an aggressive disease with limited effective therapeutic options. Clinical trials suggest an additive effect of chemotherapy and immunotherapy in SCLC, although the magnitude of benefit seems to be limited. Considering the prolonged peripheral persistence...

E. Gobbini, M. H. Diallo, C. Clément-Duchêne et al. · ESMO Open · 0 citations